Literature DB >> 922745

Disordered nocturnal prolactin regulation in women with breast cancer.

W B Malarkey, L L Schroeder, V C Stevens, A G James, R R Lanese.   

Abstract

Mean 24-hr prolactin concentrations were determined in 25 female control subjects, 16 women with benign breast masses, and 23 subjects with breast cancer. This evaluation performed before breast surgery revealed significantly decreased (p less than 0.02) nocturnal (12 a.m. to 7 a.m.) prolactin concentrations in 12 postmenopausal breast cancer subjects that contrasted with significantly increased (p less than 0.05) nocturnal prolactin levels in five luteal-phase premenopausal women with breast cancers. Prolactin concentrations in patients with benign breast disease were not significantly different from control subjects. Two of the premenopausal breast cancer patients had marked preoperative elevations in their mean 24-hr prolactin levels, and they were two of the three subjects who have since expired. Nocturnal prolactin secretion was significantly decreased (p less than 0.03) in four premenopausal breast cancer patients when they were studied 1 year after surgery; however, it remained the same in the eight postmenopausal breast cancer patients similarly evaluated. Although disordered prolactin regulation has been found in these women with breast cancer, its role in the etiology and progression of human cancer is still uncertain.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 922745

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

2.  Prolactin secretion and dehydroepiandrosterone sulphate plasma levels in women with benign breast disease.

Authors:  E Parlati; I Liberale; A Travaglini; P Morelli; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

Review 3.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

4.  Treatment of benign breast disease with bromocriptine.

Authors:  A Mussa; L Dogliotti
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

5.  Effect of Chinese medical herbs-Huiru Yizeng Yihao on hyperprolactinemia and hyperplasia of mammary gland in mice.

Authors:  Xiong Wang; Yong-Gang Chen; Li Ma; Zhi-Hui Li; Ju-Yi Li; Xin-Guo Liu; Ji-Li Zou; Jin-Hu Wu
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-05-16

Review 6.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

7.  Host heterogeneity in female breast cancer: possible significance for pathophysiology, therapy, and prevention.

Authors:  P Cohen
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

8.  Hormonal profile in benign breast disease. Endocrine status of cyclical mastalgia patients.

Authors:  E Parlati; A Travaglini; I Liberale; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

9.  Elevated levels of prolactin in nulliparous women.

Authors:  M C Yu; V R Gerkins; B E Henderson; J B Brown; M C Pike
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

10.  A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.

Authors:  Sulggi A Lee; Christopher A Haiman; Noel P Burtt; Loreall C Pooler; Iona Cheng; Laurence N Kolonel; Malcolm C Pike; David Altshuler; Joel N Hirschhorn; Brian E Henderson; Daniel O Stram
Journal:  BMC Med Genet       Date:  2007-12-01       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.